Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Diagnosis of prostate cancer.

Descotes JL.

Asian J Urol. 2019 Apr;6(2):129-136. doi: 10.1016/j.ajur.2018.11.007. Epub 2019 Feb 14. Review.

2.

Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.

Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A.

Eur Urol. 2015 Dec;68(6):1045-53. doi: 10.1016/j.eururo.2015.01.013. Epub 2015 Feb 2. Review.

PMID:
25656808
3.

New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.

Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2. Review.

PMID:
26850970
4.

68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.

Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.

5.

Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?

Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo C, Gallucci M, Catalano C.

Eur Urol. 2018 Jul;74(1):48-54. doi: 10.1016/j.eururo.2018.03.007. Epub 2018 Mar 19.

PMID:
29566957
6.

Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.

Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S.

Eur Urol. 2017 Aug;72(2):282-288. doi: 10.1016/j.eururo.2016.08.041. Epub 2016 Aug 27.

PMID:
27574821
7.

The current role of prostate multiparametric magnetic resonance imaging.

Rouviere O, Moldovan PC.

Asian J Urol. 2019 Apr;6(2):137-145. doi: 10.1016/j.ajur.2018.12.001. Epub 2018 Dec 11. Review.

8.

A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.

De Visschere PJL, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, Maurer T, Hadaschik BA, Lecouvet FE, Giannarini G, Fanti S.

Eur Urol Oncol. 2019 Feb;2(1):47-76. doi: 10.1016/j.euo.2018.09.010. Epub 2018 Oct 24. Review.

PMID:
30929846
9.

Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.

Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, Thompson LC.

Eur Urol. 2014 Jul;66(1):22-9. doi: 10.1016/j.eururo.2014.03.002. Epub 2014 Mar 14.

PMID:
24666839
10.

Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?

Pepe P, Garufi A, Priolo G, Pennisi M.

Clin Genitourin Cancer. 2015 Feb;13(1):e27-30. doi: 10.1016/j.clgc.2014.06.013. Epub 2014 Jun 21.

PMID:
25081324
11.

Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.

Tonttila PP, Lantto J, Pääkkö E, Piippo U, Kauppila S, Lammentausta E, Ohtonen P, Vaarala MH.

Eur Urol. 2016 Mar;69(3):419-25. doi: 10.1016/j.eururo.2015.05.024. Epub 2015 May 29.

PMID:
26033153
12.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
13.

18F-Choline Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for the Detection of Early Local Recurrence of Prostate Cancer Initially Treated by Radiation Therapy: Comparison With Systematic 3-Dimensional Transperineal Mapping Biopsy.

Kanoun S, Walker P, Vrigneaud JM, Depardon E, Barbier V, Humbert O, Moulin M, Créhange G, Cormier L, Loffroy R, Brunotte F, Cochet A.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):986-994. doi: 10.1016/j.ijrobp.2016.12.025. Epub 2016 Dec 28.

PMID:
28333020
14.

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.

Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.

PMID:
28336078
15.

A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.

Hendriks RJ, van der Leest MMG, Dijkstra S, Barentsz JO, Van Criekinge W, Hulsbergen-van de Kaa CA, Schalken JA, Mulders PFA, van Oort IM.

Prostate. 2017 Oct;77(14):1401-1407. doi: 10.1002/pros.23401. Epub 2017 Aug 29.

PMID:
28853167
16.

A prospective study investigating the impact of multiparametric MRI in biopsy-naïve patients with clinically suspected prostate cancer: The PROKOMB study.

Baur ADJ, Henkel T, Johannsen M, Speck T, Weißbach L, Hamm B, König F.

Contemp Clin Trials. 2017 May;56:46-51. doi: 10.1016/j.cct.2017.03.001. Epub 2017 Mar 6.

PMID:
28279782
17.

Value of bimodal (18)F-choline-PET/MRI and trimodal (18)F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy.

Paparo F, Piccardo A, Bacigalupo L, Romagnoli A, Piccazzo R, Monticone M, Cevasco L, Campodonico F, Conzi GM, Carmignani G, Rollandi GA.

Abdom Imaging. 2015 Aug;40(6):1772-87. doi: 10.1007/s00261-014-0345-0.

PMID:
25579170
18.

Multiparametric (mp) MRI of prostate cancer.

Kumar V, Bora GS, Kumar R, Jagannathan NR.

Prog Nucl Magn Reson Spectrosc. 2018 Apr;105:23-40. doi: 10.1016/j.pnmrs.2018.01.001. Epub 2018 Jan 31. Review.

PMID:
29548365
19.

Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.

Schiavina R, Brunocilla E, Borghesi M, Vagnoni V, Castellucci P, Nanni C, Ceci F, Gacci M, Martorana G, Fanti S.

Rev Esp Med Nucl Imagen Mol. 2013 Sep-Oct;32(5):310-3. doi: 10.1016/j.remn.2013.06.003. Epub 2013 Aug 9.

PMID:
23933383
20.

Nuclear medicine studies of the prostate, testes, and bladder.

Jana S, Blaufox MD.

Semin Nucl Med. 2006 Jan;36(1):51-72. Review.

PMID:
16356796

Supplemental Content

Support Center